• OUR RESEARCH
    • NASH
    • Targets & Clinical Progress
    • Posters/Publications
  • OUR PIPELINE
    • Pipeline
    • Clinical Trials
    • Expanded Access Policy
  • OUR STORY
    • Overview
    • Management Team
    • Partnership
  • NEWS
  • CAREERS

OUR RESEARCH

  • NASH
  • Targets & Clinical Progress
  • Posters/Publications

OUR PIPELINE

  • Pipeline
  • Clinical Trials
  • Expanded Access Policy

OUR STORY

  • Overview
  • Management Team
  • Partnership

NEWS

CAREERS

News

  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • Ascletis’ NASH Drug ASC41(THRβ) Phase II Enrollment is Progressing as Planned

    21/12/2022

  • Ascletis Announces Poster Presentation of Phase I, Single-Dose Study of ASC43F for NASH at AASLD Annual Meeting 2022

    07/11/2022

  • SAGIMET BIOSCIENCES ANNOUNCES POSITIVE INTERIM PHASE 2B CLINICAL TRIAL DATA WITH DENIFANSTAT (TVB-2640), A FIRST-IN-CLASS FATTY ACID SYNTHASE INHIBITOR, IN MODERATE-TO-SEVERE NON-ALCOHOLIC STEATOHEPATITIS (NASH) PATIENTS

    04/11/2022

  • Ascletis Announces Dosing of the First Patient in Phase II Clinical Trial of THRβ Agonist ASC41 for 52-Week Treatment of Liver Biopsy-Proven NASH

    05/10/2022

  • Gannex Announces First Subject Dosed in the U.S. Drug-Drug Interaction Study of FXR Agonist ASC42 for Treatment of Primary Biliary Cholangitis

    16/08/2022

  • Gannex Announces U.S. FDA Clearance of Clinical Trial on FXR Agonist ASC42 for Treatment of Primary Biliary Cholangitis

    08/06/2022

  • Gannex Announces First Patient Dosed in Phase II Clinical Trial of ASC42, an FXR Agonist, for Primary Biliary Cholangitis

    10/04/2022

  • Gannex Announces Completion of the U.S. Phase I Trial of ASC43F, an In-House Developed First-in-Class Dual Targeting Fixed-dose Combination Tablet for NASH

    04/01/2022

FIND US:

All contents © Copyright Gannex Pharma Co., Ltd.All Rights Reserved

This site is published by Gannex Pharma Co., Ltd.

which is solely responsible for all site content.